Validation of the Individualized Metabolic Surgery score in predicting long‐term remission of diabetes after duodenal switch‐type procedures

Abstract

AbstractAimTo validate the Individualized Metabolic Surgery (IMS) score and assess long‐term remission of type 2 diabetes (T2D) after duodenal switch (DS)‐type procedures in patients with obesity. In addition, to help guide metabolic procedure selection for those patients categorized as having severe T2D.Materials and MethodsThis is a retrospective single cohort study of all patients with T2D and severe obesity, who underwent DS‐type procedures at a single institution from December 2010 to December 2018. Study endpoints included validating the IMS score in our cohort and evaluating the impact of DS‐type procedures on long‐term (≥ 5 years) remission of T2D, especially in patients with severe disease. A receiver operator characteristic curve was used to assess the accuracy of the IMS score using the area under the curve (AUC).ResultsThe study cohort included 30 patients with complete baseline and long‐term glycaemic data after their index DS‐type surgery. Twelve patients (40%) were classified with severe T2D, and the distribution of IMS‐based severity groups was similar between our cohort and the original IMS study (P = .42). IMS scores predicted long‐term T2D remission with AUC = 0.77. Patients with IMS‐based severe diabetes achieved significantly higher long‐term remission after DS‐type procedures compared with gastric bypass and/or sleeve gastrectomy from the original IMS study (42% vs. 12%; P < .05).ConclusionsThe IMS score properly classifies the severity of T2D in our study cohort and adequately predicts its long‐term remission after DS‐type procedures. While T2D remission decreases with more severe IMS scores, long‐term remission remains high after DS‐type procedures among patients with severe disease.